CSL has posted a $US2.19 billion ($A3.38 billion) web revenue after tax, down three per cent from a yr in the past as forex fluctuations took a chew out of the blood product big’s earnings.
Adjusted for forex fluctuations, CSL’s web revenue rose eight per cent to $US2.44 billion. On a continuing forex foundation, CSL’s income grew 31 per cent to $US13.31 billion.
“”Our robust efficiency within the 2023 monetary yr was delivered towards a difficult working atmosphere,” CSL chief executive and managing director Dr Paul McKenzie said.
“While we’ve not been resistant to inflation and forex headwinds, our concentrate on enhancing efficiencies throughout our world community of producing websites has helped us cut back the impression.”
Plasma collections rose 31 per cent to record levels as social mobility increased following the end of the pandemic, even as CSL trimmed donor compensation.
Targeted marketing campaigns and enhanced digital initiatives to attract donors contributed to what CSL called an unprecedented growth in collections.
Dr McKenzie said a highlight of the year was undoubtedly treating the first patients with Hemgenix, a gene therapy for adults with a rare genetic bleeding disorder known as Hemophilia B.
The once-only treatment uses a genetically modified virus expressed in the liver that creates the blood-clotting protein Factor IX, limiting bleeding episodes.
The IV infusion was approved in the US in November and is under evaluation by the Therapeutic Goods Administration in Australia.
CSL declared a ultimate dividend of US$1.29 per share, for a complete full-year dividend of $US2.36 per share. In Australian forex, that involves $3.59 per share, up 13 per cent from a yr in the past.
Source: www.perthnow.com.au
